Nardoguaianone L Isolated from Nardostachys jatamansi Improved the Effect of Gemcitabine Chemotherapy via Regulating AGE Signaling Pathway in SW1990 Cells
Open Access
Abstract
Pancreatic cancer is the seventh leading cause of cancer-related death worldwide and is known as “the king of cancers”. Currently, gemcitabine (GEM) as the clinical drug of choice for chemotherapy of advanced pancreatic cancer has poor drug sensitivity and ineffective chemotherapy. Nardoguaianone L (G-6) is a novel guaiane-type sesquiterpenoid isolated from Nardostachys jatamansi DC., and it exhibits anti-tumor activity. Based on the newly discovered G-6 with anti-pancreatic cancer activity in our laboratory, this paper aimed to evaluate the potential value of the combination of G-6 and GEM in SW1990 cells, including cell viability, cell apoptosis, colony assay and tandem mass tags (TMT) marker-based proteomic technology. These results showed that G-6 combined with GEM significantly inhibited cell viability, and the effect was more obvious than that with single drug. In addition, the use of TMT marker-based proteomic technology demonstrated that the AGE-RAGE signaling pathway was activated after medication-combination. Furthermore, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) assays were used to validate the proteomic results. Finally, apoptosis was detected by flow cytometry. In conclusion, G-6 combined with GEM induced an increase in ROS level and a decrease in MMP in SW1990 cells through the AGE-RAGE signaling pathway, ultimately leading to apoptosis. G-6 improved the effect of GEM chemotherapy and may be used as a potential combination therapy for pancreatic cancer.Keywords
Funding Information
- National Natural Science Foundation of China (32161143019, 20JR10RA061, 21JR7RA075, E20458YZ, ZYFZFX-6, E2054ASL)
- Outstanding Youth Fund of Gansu Province (32161143019, 20JR10RA061, 21JR7RA075, E20458YZ, ZYFZFX-6, E2054ASL)
- National Natural Science Foundation of China (32161143019, 20JR10RA061, 21JR7RA075, E20458YZ, ZYFZFX-6, E2054ASL)
- Chinese Academy of Sciences via Special Research Assistant Program (32161143019, 20JR10RA061, 21JR7RA075, E20458YZ, ZYFZFX-6, E2054ASL)
- CAS “Light of West China” Program, Major Program of the Lanzhou Institute of Chemical Physics (32161143019, 20JR10RA061, 21JR7RA075, E20458YZ, ZYFZFX-6, E2054ASL)
- LICP Cooperation Foundation for Young Scholars (32161143019, 20JR10RA061, 21JR7RA075, E20458YZ, ZYFZFX-6, E2054ASL)
This publication has 40 references indexed in Scilit:
- Phenotypic differences in hiPSC NPCs derived from patients with schizophreniaMolecular Psychiatry, 2014
- Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabineApoptosis, 2013
- Integrative Prediction of Gene Function and Platinum-Free Survival from Genomic and Epigenetic Features in Ovarian Cancer2013
- LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cellsCurrent Medical Science, 2013
- Current concepts and novel targets in advanced pancreatic cancerGut, 2012
- Pancreatic cancerThe Lancet, 2011
- Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinomaInternational Journal of Cancer, 2010
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nature Reviews Drug Discovery, 2009
- Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cellsBioorganic & Medicinal Chemistry, 2006